On Tuesday, Mizuho (NYSE:MFG) Securities updated its outlook on shares of ADMA Biologics (NASDAQ:ADMA), increasing the price target to $28 from the previous $24 while maintaining an Outperform rating.
The upgrade comes as ADMA demonstrates remarkable market performance, with a 319.91% year-to-date return and strong financial health metrics according to InvestingPro data. This adjustment reflects the firm's recognition of ADMA's continued progress and profitability, particularly with its products ASCENIV and BIVIGAM.
ASCENIV, used for primary Immunodeficiency (PI) patients who do not respond to other immunoglobulin (Ig) therapies, is gaining momentum. The industry's supply constraints, a carryover from the pandemic, have also allowed BIVIGAM to perform well in head-to-head comparisons with competing Ig products.
Mizuho anticipates that the manufacturing standardization and yield enhancement efforts will further support profitability, especially as the company has seen a consistent rise in profitability since the first quarter of 2024.
ADMA Biologics concluded the third quarter of 2024 with over 50% of its product mix attributed to ASCENIV, similar to the second quarter, although specific mix percentages were not disclosed by management. The firm expects the shift towards ASCENIV to continue, noting that even a small increase in market penetration could significantly boost sales and EBITDA.
The revised financial targets for ADMA Biologics are optimistic, with revenue projections increased to over $415 million for 2024 and $465 million for 2025, up from the previous forecasts of $400 million and $445 million, respectively.
The company's adjusted EBITDA for 2025 is now anticipated to exceed $215 million, which would represent an operating margin of at least 40%, supported by favorable product mixes and cost control measures. InvestingPro analysis shows the company maintains a healthy current ratio of 7.09 and operates with moderate debt levels, suggesting strong financial stability. Discover more insights and 13 additional ProTips with an InvestingPro subscription.
Mizuho's analysis places ADMA Biologics among the top 10% of its high-growth, profitable peers, citing over 20% top-line growth and more than 50% EBITDA growth profiles. With a remarkable revenue growth of 63.39% in the last twelve months and an "GREAT" overall financial health score from InvestingPro, this positive outlook is seen as a result of the company's strategic efforts and the strong performance of its specialty immunoglobulin therapies.
In other recent news, ADMA Biologics has seen substantial growth in its third-quarter earnings for 2024. The company's total revenues reached $119.8 million, a 78% increase compared to the previous year, while net income surged by 1,300% to $35.9 million. Looking forward, the company has revised its financial expectations upwards, forecasting revenues of over $415 million for 2024 and $465 million for 2025.
In terms of organizational changes, ADMA Biologics announced board adjustments including the appointment of Young T. Kwon, PhD, as the new Chairman of the Audit Committee. This comes after the resignation of Bryant E. Fong, reflecting the company's commitment to strong corporate governance and oversight. These are some of the recent developments in the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.